Our analysis of 441 GLP-1 pathway assets reveals a striking pattern. Massive patient populations with proven GLP-1 science are systematically underserved.

OSA, PCOS, and diabetic retinopathy represent 1.1B patients with validated mechanism science but 10-20x less competitive intensity.

Obstructive sleep apnea: 936 million adults globally, 50% abandon CPAP devices, zero FDA-approved drugs. The opportunity isn't incremental patients, it's reimbursement arbitrage. While 70% of OSA patients are obese and addressable by existing programs, an OSA-specific indication transforms the commercial equation. Obesity faces payer resistance and formulary barriers. OSA with documented CPAP failure establishes medical necessity, bypasses step therapy, and unlocks better access for the same 655 million patients. Only 15 GLP-1 drugs target OSA; just 8 in active development.

PCOS: 100 million women globally, no FDA-approved treatments. Current standard of care is off-label metformin - managing symptoms without addressing metabolic dysfunction. GLP-1 agonists restore insulin sensitivity and improve ovulation. Only 9 drugs pursue PCOS, all as label expansions of approved products.

Diabetic retinopathy: 103 million patients, leading cause of working-age blindness. GLP-1s show retinal protection in cardiovascular trials, yet only 29 programs target this explicitly.

The most valuable metabolic franchises won't come from out-competing Lilly and Novo in obesity - they'll come from redeploying GLP-1 science where indication choice creates reimbursement advantages.